+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Glioma Treatment Market - Global Forecast 2026-2032- Product Image
Glioma Treatment Market - Global Forecast 2026-2032- Product Image
New

Glioma Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5968146
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The glioma treatment market is rapidly evolving as scientific breakthroughs, clinical innovations, and industry forces intersect, prompting healthcare leaders to reconsider established care pathways and commercial strategies.

Market Snapshot: Glioma Treatment Market Growth

The Glioma Treatment Market grew from USD 5.70 billion in 2025 to USD 6.10 billion in 2026, and is expected to advance at a CAGR of 7.72%, reaching USD 9.60 billion by 2032. This expansion is largely attributed to advancements in molecular diagnostics, greater integration of personalized therapies, and ongoing evolution of care delivery models. Senior executives, portfolio strategists, and clinical leaders can identify emerging opportunities and risks as evolving technology, regulatory shifts, and new tariffs increasingly shape market potential.

Scope & Segmentation

  • Therapeutic Modalities: Chemotherapy agents, immunotherapies, radiotherapy modalities, surgical approaches, and targeted treatments aligned to EGFR and VEGF pathways.
  • Product Types: Innovative branded biologics, small molecules, generic formulations, and device-enabled solutions addressing various competitive contexts.
  • Disease Grade: High-grade tumors—including anaplastic astrocytoma and glioblastoma multiforme—as well as low-grade gliomas such as diffuse astrocytoma and oligodendroglioma.
  • Molecular Profiles: IDH status, MGMT methylation, and other biomarkers driving diagnostic selection and therapeutic targeting.
  • Patient Demographics: Adult and pediatric populations, with further stratification by age cohort to inform dosing and monitoring protocols.
  • Lines of Therapy: First-line and recurrent settings, shaping reimbursement dynamics and evidence requirements.
  • Care Settings: Ambulatory surgery centers, cancer research institutes, clinics, and hospitals, each with distinctive expertise and infrastructure needs.
  • Geographies: Americas, Europe Middle East and Africa, and Asia-Pacific, with unique regulatory, reimbursement, and care delivery landscapes.

Key Takeaways for Decision-Makers

  • Continued advances in precision oncology and molecular diagnostics are fundamentally altering the therapeutic landscape, enabling deeper patient stratification and refined treatment selection.
  • The convergence of immunotherapy, targeted agents, and established modalities is paving the way for integrated multimodal regimens that push beyond incremental improvements.
  • Adaptive clinical trial designs, such as basket and umbrella studies, are accelerating clinical development and enabling more agile portfolio management in rapidly stratified patient cohorts.
  • Stakeholder collaboration—including pharmaceutical sponsors, biotechnology companies, academic research sites, and clinical service vendors—is essential to unlocking operational efficiencies and translational expertise.
  • Growing focus on supply chain agility and manufacturing resilience addresses commercial risks associated with shifting tariffs, complex cold chains, and a preference for outpatient-ready therapeutic formats.
  • Region-specific regulatory frameworks, payer expectations, and infrastructure capacities mean that successful commercialization strategies must be tailored for each market’s unique clinical ecosystem.

Tariff Impact on Supply Chain and Product Strategy

Tariff policy shifts within key markets, notably the United States, are prompting manufacturers to re-evaluate sourcing, supply chain resilience, and product design for glioma therapeutics. Increased costs or complexity in cross-border transport drive interest in nearshoring, strategic supplier partnerships, and decentralized manufacturing. For commercial leaders, this climate encourages innovation in product features, such as outpatient delivery and simplified storage requirements, to enhance market access and flexibility for payers and providers.

Methodology & Data Sources

This analysis draws on a rigorous mixed-methods approach, integrating peer-reviewed literature, regulatory guidelines, expert interviews, clinical trial data, and public company disclosures. Scenario analysis and cross-source triangulation ensure robust, clinically relevant market insights while highlighting inflection points and operational contingencies.

Why This Report Matters

  • Provides a comprehensive and actionable framework to navigate complex clinical, regulatory, and commercial changes in glioma care.
  • Delivers strategic clarity on emerging therapeutic, diagnostic, and regional opportunities within the evolving oncology landscape.
  • Enables senior leaders to align investment, development, and market entry strategies with the latest evidence and stakeholder needs.

Conclusion

Integrated diagnostic, therapeutic, and operational strategies are now essential for success in glioma treatment. Organizations that combine robust evidence generation with manufacturing agility and regionally attuned commercialization will be best positioned to deliver meaningful clinical results and business outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Glioma Treatment Market, by Treatment Modality
8.1. Chemotherapy
8.1.1. Alkylating Agents
8.1.2. Anti-Microtubule Agents
8.2. Immunotherapy
8.2.1. Car T-Cell Therapy
8.2.2. Checkpoint Inhibitors
8.2.3. Vaccines
8.3. Radiotherapy
8.3.1. Brachytherapy
8.3.2. External Beam Radiotherapy
8.4. Surgery
8.5. Targeted Therapy
8.5.1. Egfr Inhibitors
8.5.2. Vegf Inhibitors
9. Glioma Treatment Market, by Product Type
9.1. Branded
9.2. Generic
10. Glioma Treatment Market, by Glioma Grade
10.1. High Grade
10.1.1. Anaplastic Astrocytoma
10.1.2. Glioblastoma Multiforme
10.2. Low Grade
10.2.1. Diffuse Astrocytoma
10.2.2. Oligoastrocytoma
10.2.3. Oligodendroglioma
11. Glioma Treatment Market, by Line Of Therapy
11.1. First Line
11.2. Second Line
11.3. Third Line
12. Glioma Treatment Market, by Molecular Subtype
12.1. Idh Mutant
12.2. Idh Wildtype
12.3. Mgmt Methylation Positive
12.4. Mgmt Unmethylated
13. Glioma Treatment Market, by Patient Age
13.1. Adult
13.2. Pediatric
14. Glioma Treatment Market, by End User
14.1. Ambulatory Surgical Centers
14.2. Cancer Research Institutes
14.3. Clinics
14.4. Hospitals
15. Glioma Treatment Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Glioma Treatment Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Glioma Treatment Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Glioma Treatment Market
19. China Glioma Treatment Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. AbbVie Inc.
20.6. Amgen Inc.
20.7. Arbor Pharmaceuticals LLC
20.8. AstraZeneca PLC
20.9. Aurobindo Pharma Limited
20.10. Bayer AG
20.11. Bristol-Myers Squibb Company
20.12. Cipla Limited
20.13. Dr. Reddy's Laboratories Ltd.
20.14. Eisai Co. Ltd.
20.15. Eli Lilly and Company
20.16. GlaxoSmithKline PLC
20.17. Hikma Pharmaceuticals PLC
20.18. Ipsen Biopharmaceuticals Inc.
20.19. Johnson & Johnson
20.20. Lupin Limited
20.21. Merck & Co. Inc.
20.22. Mylan N.V.
20.23. Novartis AG
20.24. Pfizer Inc.
20.25. Roche Holding AG
20.26. Sanofi S.A.
20.27. Sun Pharmaceutical Industries Ltd.
20.28. Takeda Pharmaceutical Company Limited
20.29. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 165. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. EUROPE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 182. EUROPE GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 183. EUROPE GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 184. EUROPE GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 185. EUROPE GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 186. EUROPE GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 187. EUROPE GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 188. EUROPE GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 189. EUROPE GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 191. EUROPE GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 192. EUROPE GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 193. EUROPE GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 204. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 205. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 206. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 207. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 210. AFRICA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 211. AFRICA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 212. AFRICA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 213. AFRICA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 214. AFRICA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 215. AFRICA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 216. AFRICA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 217. AFRICA GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 218. AFRICA GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 219. AFRICA GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 220. AFRICA GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 221. AFRICA GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 230. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 231. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 232. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 233. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 234. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 235. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 237. ASEAN GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 238. ASEAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 239. ASEAN GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 240. ASEAN GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 241. ASEAN GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 242. ASEAN GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 243. ASEAN GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 244. ASEAN GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 245. ASEAN GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 246. ASEAN GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 247. ASEAN GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 248. ASEAN GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 249. ASEAN GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 250. ASEAN GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. GCC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 252. GCC GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 253. GCC GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 254. GCC GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 255. GCC GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 256. GCC GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 257. GCC GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 258. GCC GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 259. GCC GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 260. GCC GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 261. GCC GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 262. GCC GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 263. GCC GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 264. GCC GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 279. BRICS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. BRICS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 281. BRICS GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 282. BRICS GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 283. BRICS GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 284. BRICS GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 285. BRICS GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 286. BRICS GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 287. BRICS GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 288. BRICS GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 289. BRICS GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 290. BRICS GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 291. BRICS GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 292. BRICS GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 293. G7 GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 294. G7 GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 295. G7 GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 296. G7 GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 297. G7 GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 298. G7 GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 299. G7 GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 300. G7 GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 301. G7 GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 302. G7 GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 303. G7 GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 304. G7 GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 305. G7 GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 306. G7 GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 307. NATO GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 308. NATO GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 309. NATO GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 310. NATO GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 311. NATO GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 312. NATO GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 313. NATO GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 314. NATO GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 315. NATO GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 316. NATO GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 317. NATO GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 318. NATO GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 319. NATO GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 320. NATO GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 323. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 324. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 325. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 326. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 327. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 328. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 329. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 330. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 331. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2032 (USD MILLION)
TABLE 332. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 333. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2032 (USD MILLION)
TABLE 334. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
TABLE 335. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 336. CHINA GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 337. CHINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
TABLE 338. CHINA GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 339. CHINA GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 340. CHINA GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
TABLE 341. CHINA GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 342. CHINA GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 343. CHINA GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2032 (USD MILLION)
TABLE 344. CHINA GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2032 (USD MILLION)
TABLE 345. CHINA GLIOMA TREATMENT MARKET S

Companies Mentioned

The key companies profiled in this Glioma Treatment market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Arbor Pharmaceuticals LLC
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen Biopharmaceuticals Inc.
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co. Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 6.1 Billion
Forecasted Market Value ( USD ) by 2032 $ 9.6 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Glioma Treatment Market Report 2025 - Product Image

Glioma Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Glioma Treatment - Global Strategic Business Report - Product Image

Glioma Treatment - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Glioma Market - A Global and Regional Analysis: Focus on Disease Type, End-user, Country, and Region, 2025-2035 - Product Image

Glioma Market - A Global and Regional Analysis: Focus on Disease Type, End-user, Country, and Region, 2025-2035

  • Report
  • Global
From
Malignant Glioma Therapeutics - Global Strategic Business Report - Product Image

Malignant Glioma Therapeutics - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Adult Malignant Glioma Therapeutics Market Report 2025 - Product Image

Adult Malignant Glioma Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Glioma Drug Market

The Glioma Drug market is a subset of the larger Brain Cancer Drug market. Glioma is a type of brain cancer that is caused by the abnormal growth of glial cells in the brain. Treatment for glioma typically involves surgery, radiation therapy, chemotherapy, and targeted therapy. Drugs used to treat glioma include temozolomide, bevacizumab, and lomustine. Glioma drugs are typically used in combination with other treatments, such as radiation and surgery, to improve patient outcomes. The market for glioma drugs is expected to grow due to the increasing prevalence of brain cancer and the development of new treatments. Some companies in the Glioma Drug market include Novartis, Merck, Roche, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.